These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31925640)

  • 1. Human immunodeficiency virus type-1 Tat protein induces secretory leukocyte protease inhibitor expression in African green monkey but not human cells.
    Özdemir S; Şengez B; Arslanoğlu A
    Virus Genes; 2020 Apr; 56(2):182-193. PubMed ID: 31925640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity.
    Jana NK; Gray LR; Shugars DC
    J Virol; 2005 May; 79(10):6432-40. PubMed ID: 15858026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced secretory leukocyte protease inhibitor in human immunodeficiency virus type 1-infected patients.
    Baqui AA; Meiller TF; Falkler WA
    Clin Diagn Lab Immunol; 1999 Nov; 6(6):808-11. PubMed ID: 10548568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism.
    Fakioglu E; Wilson SS; Mesquita PM; Hazrati E; Cheshenko N; Blaho JA; Herold BC
    J Virol; 2008 Oct; 82(19):9337-44. PubMed ID: 18667508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory function of secretory leukocyte proteinase inhibitor (SLPI) in human saliva is HIV-1 specific and varies with virus tropism.
    Skott P; Lucht E; Ehnlund M; Björling E
    Oral Dis; 2002 May; 8(3):160-7. PubMed ID: 12108760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro.
    McNeely TB; Dealy M; Dripps DJ; Orenstein JM; Eisenberg SP; Wahl SM
    J Clin Invest; 1995 Jul; 96(1):456-64. PubMed ID: 7615818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor.
    Turpin JA; Schaeffer CA; Bu M; Graham L; Buckheit RW; Clanton D; Rice WG
    Antiviral Res; 1996 Mar; 29(2-3):269-77. PubMed ID: 8739605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human immunodeficiency virus type 1 Tat induces B7-H1 expression via ERK/MAPK signaling pathway.
    Shi J; Qin X; Zhao L; Wang G; Liu C
    Cell Immunol; 2011; 271(2):280-5. PubMed ID: 21821233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Host Factors on the Regulation of Tat-Mediated HIV-1 Transcription.
    Mousseau G; Valente ST
    Curr Pharm Des; 2017; 23(28):4079-4090. PubMed ID: 28641539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of HIV Replication in Monocyte-Derived Macrophages (MDM) by Host Antiviral Factors Secretory Leukocyte Protease Inhibitor and Serpin Family C Member 1 Induced by Steroid Hormones.
    Biswas S; Chen E; Gao Y; Lee S; Hewlett I; Devadas K
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory leukocyte protease inhibitor: inhibition of human immunodeficiency virus-1 infection of monocytic THP-1 cells by a newly cloned protein.
    Shine NR; Wang SC; Konopka K; Burks EA; Düzgüneş N; Whitman CP
    Bioorg Chem; 2002 Aug; 30(4):249-63. PubMed ID: 12392704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curcumin inhibits HIV-1 by promoting Tat protein degradation.
    Ali A; Banerjea AC
    Sci Rep; 2016 Jun; 6():27539. PubMed ID: 27283735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of apoptosis and viral latency - an axis to be well understood for successful cure of human immunodeficiency virus.
    Timilsina U; Gaur R
    J Gen Virol; 2016 Apr; 97(4):813-824. PubMed ID: 26764023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
    Gupta S; Mitra D
    Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathway analysis in HEK 293T cells overexpressing HIV-1 tat and nucleocapsid.
    Lee MJ; Park JH
    J Microbiol Biotechnol; 2009 Oct; 19(10):1103-8. PubMed ID: 19884766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of the phospholipid scramblase 1 with HIV-1 Tat results in the repression of Tat-dependent transcription.
    Kusano S; Eizuru Y
    Biochem Biophys Res Commun; 2013 Apr; 433(4):438-44. PubMed ID: 23501106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I.
    Shugars DC; Sauls DL; Weinberg JB
    Oral Dis; 1997 May; 3 Suppl 1():S70-2. PubMed ID: 9456661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells.
    Farazmandfar T; Haghshenas MR; Shahbazi M
    Hum Gene Ther; 2015 Oct; 26(10):680-7. PubMed ID: 26077977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV-I.
    Wahl SM; McNeely TB; Janoff EN; Shugars D; Worley P; Tucker C; Orenstein JM
    Oral Dis; 1997 May; 3 Suppl 1():S64-9. PubMed ID: 9456660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function
    Patel S; Leibrand CR; Palasuberniam P; Couraud PO; Weksler B; Jahr FM; McClay JL; Hauser KF; McRae M
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.